Neurosearch has reported positive results from the MermaiHD study, the European Phase III study with Huntexil® (pridopidine) in Huntington’s disease. The HD community knows this drug by its original designation of ACR-16. (click here for more)
Currently the HART clinical trial to study ACR16 is enrolling in the United States, so for families excited by this news we encourage them to visit HDTrials.org or our interactive Clinical Trial map at http://www.hdsa.org/research/clinical-trials/find-your-closest-clinical-trial.html to learn about how they can get involved in the HART study.